Trial results

$EVMN — EVO301

Evommune, Inc. (EVMN) EVO301: trial results in Moderate-to-severe atopic dermatitis, 2026.

Research by Catalyst Intel · Published 2026-09-26 19:01 ET

The catalyst

"Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Austria from September 30 to October 3, 2026."

— Evommune, 8-K filed 2026-09-23 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id: EVMN-EVO301-2026
Company: Evommune, Inc.
Kind: Trial results
Indication: Moderate-to-severe atopic dermatitis
Window: 2026-10-01 – 2026-10-01
Status: bar_published

The bar

Published 2026-09-26 19:01 ET, before the event. The text below is the hashed text: paste it into the verify page and your browser will recompute the same digest.

At a glance

Pass if: At least 75% posterior probability that the active-versus-placebo EASI difference is an improve… · At least 33% placebo-adjusted improvement in EASI at Week 12

Killed if: Veto if any related serious or severe adverse event is reported · Veto if any adverse-event-led study discontinuation is reported

Great if (any one): At least 23% of treated patients achieve vIGA-AD 0/1 at Week 12, versus 0% on placebo; this is…

5 items we could not source — full detail below

EVENT EVMN-EVO301-2026
SCORED SET ITT
FLOOR floor_protocol_success At least 75% posterior probability that the active-versus-placebo EASI difference is an improvement of at least 8% over placebo at Week 12.
BAR bar_prior_easi_effect At least 33% placebo-adjusted improvement in EASI at Week 12.
DIFF differentiator_viga_response At least 23% of treated patients achieve vIGA-AD 0/1 at Week 12, versus 0% on placebo; this is a secondary-endpoint differentiator.
VETO veto_related_serious_or_severe_ae Veto if any related serious or severe adverse event is reported.
VETO veto_ae_discontinuation Veto if any adverse-event-led study discontinuation is reported.

SHA-256: 6b7f85aac708eff72be3f64923bf1e6f458ac1e57ff7d63cb925a1fd4105e866
Frozen: yes
Public post: https://x.com/i/web/status/2103983346233553180

Criteria as committed

Floor — all must pass

Id	Field	Test	As written
`floor_protocol_success`	`posterior_probability_of_easi_difference`	`>= 75`	At least 75% posterior probability that the active-versus-placebo EASI difference is an improvement of at least 8% over placebo at Week 12.

Bar — all must pass

Id	Field	Test	As written
`bar_prior_easi_effect`	`placebo_adjusted_easi_improvement`	`>= 33`	At least 33% placebo-adjusted improvement in EASI at Week 12.

Differentiators — one upgrades IN_LINE to BEAT

Id	Field	Test	As written
`differentiator_viga_response`	`viga_ad_0_1_response_rate`	`>= 23`	At least 23% of treated patients achieve vIGA-AD 0/1 at Week 12, versus 0% on placebo; this is a secondary-endpoint differentiator.

Vetoes — any one forces MISS

Id	Field	Test	As written
`veto_related_serious_or_severe_ae`	`related_serious_or_severe_ae_count`	`> 0`	Veto if any related serious or severe adverse event is reported.
`veto_ae_discontinuation`	`adverse_event_discontinuation_count`	`> 0`	Veto if any adverse-event-led study discontinuation is reported.

What we could not source before the event

No document states the primary analysis population; scored_set is null.
No full EADV dataset, complete confidence-interval set, subgroup analysis or multiplicity plan was provided.
No manual options or comparator data were supplied.
The packet does not reconcile prior posterior-mean displays: -28 [“Posterior Mean Difference -28 95% HPD Interval for Difference in Mean -43, -14”—prior_topline_pr_1] versus -32 [“Posterior Mean Difference -32 95% HPD Interval for Difference in Mean -47, -15”—prior_topline_pr_4].
analysis population: ITT — the registry lists the trial as randomized, and a randomized comparison is analysed on every randomized patient (ITT) unless the protocol says otherwise; change it in the editor if the protocol says otherwise

Verdicts

No verdict has been published for this event yet.